

Amendments to the Claims

The listing of claims will replace all prior versions and listings of claims in the application.

1-22. (Cancelled)

23. (Previously presented) An isolated antibody which specifically binds the polypeptide of SEQ ID NO:2.

24. (Previously presented) The antibody of claim 23, which specifically binds to the polypeptide of amino acids 1 to 342 of SEQ ID NO:2.

25. (Previously presented) The antibody of claim 24, which specifically binds to the polypeptide of amino acids 2 to 342 of SEQ ID NO:2.

26. (Previously presented) The antibody of claim 25, which specifically binds to the mature polypeptide produced upon cellular expression of the polypeptide of SEQ ID NO:2.

27. (Previously presented) The antibody of claim 23, wherein said antibody is polyclonal.

28. (Previously presented) The antibody of claim 23, wherein said antibody is monoclonal.

29. (Currently amended) The antibody of claim 28, wherein said antibody is produced by a method selected from the group consisting of a [the] hybridoma technique[[],] and the trioma technique[, the human B-cell hybridoma technique, and the EBV-hybridoma technique].

30. (Currently amended) The antibody of claim 29, wherein said antibody is produced by a [the] hybridoma technique.

31. (Previously presented) The antibody of claim 29, wherein said antibody is produced by the trioma technique.

32. (Currently amended) The antibody of claim 30 [claim 27], wherein said antibody is produced by the human B-cell hybridoma technique.

33. (Currently amended) The antibody of claim 30 [claim 29], wherein said antibody is produced by the EBV-hybridoma technique.

34. (Previously presented) The antibody of claim 23, wherein said antibody is chimeric.

35. (Previously presented) The antibody of claim 23, wherein said antibody is humanized.

36. (Canceled)

37. (Previously presented) The antibody of claim 23, wherein said antibody is a single-chain antibody.

38. (Previously presented) A composition comprising the antibody of claim 23, and a carrier.

39. (Previously presented) A method of producing the antibody of claim 23, comprising:

(a) introducing a polypeptide comprising 30 contiguous amino acids of SEQ ID NO: 2 into an animal; and

(b) recovering said antibody.

40. (Previously presented) An isolated antibody fragment which specifically binds to the polypeptide of SEQ ID NO:2.

41. (Previously presented) The antibody fragment of claim 40, which specifically binds to the polypeptide of amino acids 1 to 342 of SEQ ID NO:2.

42. (Previously presented) The antibody fragment of claim 41, which specifically binds to the polypeptide of amino acids 2 to 342 of SEQ ID NO:2.

43. (Previously presented) The antibody fragment of claim 42, which specifically binds to the mature polypeptide produced upon cellular expression of the polypeptide of SEQ ID NO:2.

44. (Previously presented) The antibody fragment of claim 40, wherein said antibody fragment comprises an Fab fragment.

45. (Previously presented) The antibody fragment of claim 40, wherein said antibody fragment comprises a single chain antibody fragment.

46. (Previously presented) The antibody fragment of claim 40, wherein said antibody fragment is chimeric.

47. (Previously presented) The antibody fragment of claim 40, wherein said antibody fragment is the product of an Fab expression library.

48. (Previously presented) The antibody fragment of claim 40, wherein said antibody fragment is fused to a heterologous polypeptide.

49. (Previously presented) A composition comprising the antibody fragment of claim 40, and a carrier.

50. (Previously presented) A method of producing the antibody fragment of claim 40, comprising:

(a) introducing a polypeptide comprising 30 contiguous amino acids of SEQ ID NO: 2 into an animal;

(b) recovering an antibody which specifically binds to the polypeptide of SEQ ID NO:2;

(c) cleaving said antibody; and

(d) recovering said antibody fragment.

51. (Previously presented) An isolated antibody which specifically binds the polypeptide encoded by the human cDNA in ATCC Deposit No. 209003.

52. (Previously presented) The antibody of claim 51, which specifically binds to the mature polypeptide produced upon cellular expression of the polypeptide encoded by the human cDNA in ATCC Deposit No. 209003.

53. (Previously presented) The antibody of claim 51, wherein said antibody is polyclonal.

54. (Previously presented) The antibody of claim 51, wherein said antibody is monoclonal.

55. (Currently amended) The antibody of claim 54, wherein said antibody is produced by a method selected from the group consisting of a [the] hybridoma technique[[,]] and the trioma technique[, the human B-cell hybridoma technique, and the EBV-hybridoma technique].

56. (Currently amended) The antibody of claim 55, wherein said antibody is produced by a [the] hybridoma technique.

57. (Previously presented) The antibody of claim 55, wherein said antibody is produced by the trioma technique.

58. (Currently amended) The antibody of claim 56 [claim 55], wherein said antibody is produced by the human B-cell hybridoma technique.

59. (Currently amended) The antibody of claim 56 [claim 55], wherein said antibody is produced by the EBV-hybridoma technique.

60. (Previously presented) The antibody of claim 51, wherein said antibody is chimeric.

61. (Previously presented) The antibody of claim 51, wherein said antibody is humanized.

62. (Previously presented) The antibody of claim 51, wherein said antibody is produced in transgenic mice.

63. (Previously presented) The antibody of claim 51, wherein said antibody is a single-chain antibody.

64. (Previously presented) A composition comprising the antibody of claim 51, and a carrier.

65. (Previously presented) A method of producing the antibody of claim 51, comprising:

(a) introducing a polypeptide comprising 30 contiguous amino acids of the polypeptide encoded by the human cDNA in ATCC Deposit No. 209003 into an animal; and

(b) recovering said antibody.

66. (Previously presented) An isolated antibody fragment which specifically binds to the polypeptide encoded by the human cDNA in ATCC Deposit No. 209003.

67. (Previously presented) The antibody fragment of claim 66, which specifically binds to the mature polypeptide produced upon cellular expression of the polypeptide encoded by the human cDNA in ATCC Deposit No. 209003.

68. (Previously presented) The antibody fragment of claim 66, wherein said antibody fragment comprises an Fab fragment.

69. (Previously presented) The antibody fragment of claim 66, wherein said antibody fragment comprises a single chain antibody fragment.

70. (Previously presented) The antibody fragment of claim 66, wherein said antibody fragment is chimeric.

71. (Previously presented) The antibody fragment of claim 66, wherein said antibody fragment is the product of an Fab expression library.

72. (Previously presented) The antibody fragment of claim 66, wherein said antibody fragment is fused to a heterologous polypeptide.

73. (Previously presented) A composition comprising the antibody fragment of claim 66, and a carrier.

74. (Previously presented) A method of producing the antibody fragment of claim 66, comprising:

(a) introducing a polypeptide comprising 30 contiguous amino acids of the polypeptide encoded by the human cDNA in ATCC Deposit No. 209003 into an animal;

(b) recovering an antibody which specifically binds to the polypeptide encoded by the human cDNA in ATCC Deposit No. 209003;

(c) cleaving said antibody; and

(d) recovering said antibody fragment.

75. (Withdrawn) A method to screen for a compound which binds to a polypeptide comprising amino acids 2 to 342 of SEQ ID NO:2, comprising:

(a) contacting a compound to be screened with said polypeptide; and

(b) determining if said compound binds to said polypeptide.

76. (Withdrawn) The method of claim 75, wherein said compound to be screened comprises a molecule selected from the group consisting of a small molecule, a peptide, a peptide-like molecule, a polypeptide, and an antibody.

77. (Withdrawn) A method to screen for a compound which binds to the polypeptide encoded by the human cDNA in ATCC Deposit No. 209003, comprising:
- (a) contacting a compound to be screened with said polypeptide; and
 - (b) determining if said compound binds to said polypeptide.

78. (Withdrawn) The method of claim 77, wherein said compound to be screened comprises a molecule selected from the group consisting of a small molecule, a peptide, a peptide-like molecule, a polypeptide, and an antibody.